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MedTech and 
Diagnostics
Blood Card and Vesicle-
based Medical Tests
Value proposition / USP 
The method is based on a combination of the dry blood sample (DBS) on a blood card and extracellular
vesicle (EV) array. DBS is a minimally invasive and widespread method for collecting blood samples, where
samples are transported, stored and processed easily. Combined with the EV Array´s ability to detect
extracellular vesicles from unpurified blood makes this combination promising with regard to find biomarkers
for cancer, inflammatory, metabolic, cardiovascular or neurodegenerative diseases. Another application is
diagnosing, screening and monitoring of drug resistance, making drug trials cheaper, as less blood is needed.
Business Opportunity / Objective / Commercial Perspectives
DBS combined with the EV Array, utilizes a proven, cost-effective tool with a strong diagnostic tool making
handling and processing of blood samples promising in developed and developing countries alike. The DBS-
EV Array combination would reduce the cost of acquiring blood samples, and opens the possibility for
development of home test kits.
Technology Description / Technology Summary
The proposed method is a combination of a known method for collecting blood samples used for more than 50 years, where samples are easily transported and stored as significantly less blood is required, with the EV Array, a
new method for characterization of extracellular vesicles directly from plasma without purification requiring only 10 µL of sample. The EV Array is a protein-based microarray enabling classification of multiple surface markers
simultaneously.
Development Phase / Current state
A test setup with 20 subjects has proven that it is possible to measure vesicles
from DBS, as a proof of concept. Several parameters can be optimized such as
time, temperature, buffer and quantities. A series of optimization experiments
must be performed with more donors before commercialization; this is
estimated to take 2-3 months without extensive costs.
The Inventors Contact Information
Technology Seeking:  Funding, Partner/Research Collaboration IPR Sale/Licensing
Intellectual Property Rights: Patent pending EP17206867.8, filed on Dec.13th, 2017
Invention ID: MD04
All living cells produce extracellular vesicles (EVs),
which are nano-sized compartments. They are
considered as a pivotal part of the intercellular
environment and act as important players in cell-
to-cell communication. The fact, that EVs are
involved in the development and progression of
several diseases, has formed the basis for the use
of EV analyses in a clinical setting and envisions a
great potential for using EVs as disease-related
biomarkers.
EVs are a heterogeneous population of
membrane-enclosed vesicles that can be divided
into a number of subpopulations based on
specific characteristics such as size, biogenesis,
cellular origin, protein composition, and biological
function. The two major subtypes of EVs are
exosomes and microvesicles.
Extracellular Vesicles (EVs)
Venous blood is a convenient source of circulating extracellular vesicles (EVs). However, blood
sampling requires authorized personnel and immediate purification of the vesicles. The present
study demonstrate that intact EVs can in fact be obtained from dried blood card samples (or dried
blood spots; DBS), which can be prepared by unauthorized personnel, or even at home by the
user and shipped by regular mail. Intact EVs can be detected in extracts from dried blood spot
samples even after prolonged storage.
Being able to isolate and characterize small EVs from DBS opens up a number of new
opportunities such as monitoring of disease, e.g. progression of cancer and response to
treatment, only with involvement of a lab technician and responsible clinician.
More Information
Detailed information about the 
technology can be found at: 
WWW.EVARRAY.DK
Blood samples for the dried blood cards was obtained from the fingertips of the donors using a
lancet. The blood drops thoroughly saturated the paper (blood card especially designed for whole
cells) and was allowed to air dry before storage and isolation of small EVs according to the protocol
below. To evaluate the EV concentration and composition, the samples were analyzed using the EV
Array (Jørgensen et al., 2013, JEV) using antibodies against 15 selected surface-markers. This
proof-of-concept study persisted of an experiment with blood from 20 healthy volunteers. The
blood samples were used to test the effect of prolonged storage of the dried blood cards. The
most optimal extraction procedure was used to compare the EV contents after 1 hour, 7, 14 and 21
days after collection.
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The qualitative tests revealed that, for most of
the markers (11 out of 15), the samples from
DBS showed similar results as for blood drawn
using EDTA or CPDA collection tubes. After 21
days of storage at room temperature, a higher
degree of hemolysis were observed in the
extracted samples (see top graph for Quality
Control). The increase in free hemoglobin
generated a higher background signal, but the
samples were still acceptable for analysis with
the EV Array.
The analysis of small EVs carrying CD9 showed
that all 20 persons were tested positive both
with CPDA, EDTA and DBS. Furthermore, it was
still possible to get a positive signal after 21
days of storage at room temperature. For
CD63, the responses from DBS were equal to
EDTA plasma although a decrease were seen
after 2 weeks of storage.
A refinement of the extraction procedure will
be performed to obtain the most optimal
condition for a future qualitative analysis of
small EVs sampled as DBS.
Storage Testing
General Protocol
